Orchestrating networks in the biopharmaceutical industry: small hub firms can do it

The biopharmaceutical industry has been one of the most dynamic and promising sectors. The entry of Biotechnology start-ups in the 1980s led to the reconfiguration of the drug development value chain and the emergence of new competences. As the sector evolved, specialised firms appeared. As the industry matures, the production process becomes more specialised to support optimisation of technological steps. Our case studies reveal that the coordination of networks can be specialised, with the emergence of Dedicated Coordinating Firms. On the basis of four case studies of European biotechnology companies within a business model approach, this article helps understanding how coordinating a network can be successful and how small hub firms can do it.

[1]  P. Danzon,et al.  Productivity in Pharmaceutical Biotechnology R&D: The Role of Experience and Alliances , 2003, Journal of health economics.

[2]  Jing Zhang,et al.  Technological Knowledge Base, R&D Organization Structure and Alliance Formation: Evidence from the Biopharmaceutical Industry , 2007 .

[3]  W. Powell,et al.  Interorganizational Collaboration and the Locus of Innovation: Networks of Learning in Biotechnology. , 1996 .

[4]  Colin Campbell,et al.  Using brand personality to assess whether biotechnology firms are saying the right things to their network , 2008 .

[5]  Vincent Mangematin,et al.  Going Virtual in the European Biopharmaceutical Industry: Conductors and Oxpeckers Make It , 2008, Virtual Enterprises and Collaborative Networks.

[6]  D. Teece.  Managing Intellectual Capital: Organizational, Strategic, and Policy Dimensions , 2000 .

[7]  Yves Pigneur,et al.  Clarifying Business Models: Origins, Present, and Future of the Concept , 2005, Commun. Assoc. Inf. Syst..

[8]  Joel A. C. Baum,et al.  Don't go it alone: alliance network composition and startups' performance in Canadian biotechnology , 2000 .

[9]  Arvind Parkhe,et al.  Orchestrating Innovation Networks , 2006 .

[10]  B. Kogut,et al.  INTERFIRM COOPERATION AND STARTUP INNOVATION IN THE BIOTECHNOLOGY INDUSTRY. , 1993 .

[11]  J. DiMasi,et al.  The cost of biopharmaceutical R&D: is biotech different? , 2007 .

[12]  Christel Lane,et al.  The External Sourcing of Technological Knowledge by US Pharmaceutical Companies: Strategic Goals and Inter‐organizational Relationships , 2007 .

[13]  H. Chesbrough,et al.  Innovating Business Models with Co-Development Partnerships , 2007 .

[14]  Joseph R. D’cruz,et al.  The theory of the flagship firm , 1997 .

[15]  Andrea Bonaccorsi,et al.  The Evolution of Knowledge and the Dynamics of an Industry Network , 1997 .

[16]  M. Sawhney,et al.  Where value lives in a networked world. , 2001, Harvard business review.

[17]  Gianni Lorenzoni,et al.  Creating a Strategic Center to Manage a Web of Partners , 1995 .

[18]  D. Teece.  Profiting from technological innovation: Implications for integration, collaboration, licensing and public policy , 1993 .

[19]  Ursula Weisenfeld,et al.  Technology management and collaboration profile: virtual companies and industrial platforms in the high‐tech biotechnology industries , 2001 .

[20]  K. Eisenhardt.  Building theories from case study research , 1989, STUDI ORGANIZZATIVI.

[21]  Hong Cheong Looi,et al.  E-Commerce Adoption in Brunei Darussalam: A Quantitative Analysis of Factors Influencing Its Adoption , 2005, Commun. Assoc. Inf. Syst..

[22]  Amalya L. Oliver,et al.  Social Networks, Learning, and Flexibility: Sourcing Scientific Knowledge in New Biotechnology Firms , 1994 .

[23]  F. Rothaermel,et al.  The Effect of General and Partner-Specific Alliance Experience on Joint R&D Project Performance , 2005 .

[24]  Gaurav Laroia,et al.  Managing Drug Discovery Alliances For Success , 2005 .

[25]  Kyung Hwan Kang,et al.  Supply chain model for the semiconductor industry in consideration of manufacturing characteristics , 2006 .

[26]  Nicolaj Siggelkow.  Persuasion with case studies , 2007 .

[27]  R. W. Hansen,et al.  The price of innovation: new estimates of drug development costs. , 2003, Journal of health economics.

[28]  Khaleel Malik,et al.  The Growth and Management of R&D Outsourcing: Evidence from UK Pharmaceuticals , 2008 .

[29]  Oliver Gassmann,et al.  Leading Pharmaceutical Innovation: Trends and Drivers for Growth in the Pharmaceutical Industry , 2004 .

[30]  Paul Nightingale,et al.  The myth of the biotech revolution: An assessment of technological, clinical and organisational change , 2007 .

[31]  Anil K. Gupta,et al.  Strategic innovation: a conceptual road map , 2001 .

[32]  D. Teece,et al.  Organizing for innovation: When is virtual virtuous? , 2002 .

[33]  J. Fisken,et al.  Business models and investment trends in the biotechnology industry in Europe , 2002 .

[34]  Vincent Mangematin,et al.  Do Science and Money Go Together? The Case of the French Biotech Industry , 2008 .

[35]  A. Pettigrew.  Longitudinal Field Research on Change: Theory and Practice , 1990 .

[36]  Oliver Gassmann,et al.  Organizing Pharmaceutical Innovation: From Science‐based Knowledge Creators to Drug‐oriented Knowledge Brokers , 2005 .

[37]  W. Powell.  Learning from Collaboration: Knowledge and Networks in the Biotechnology and Pharmaceutical Industries , 1998 .

[38]  A. Arora,et al.  Evaluating technological information and utilizing it: Scientific knowledge, technological capability, and external linkages in biotechnology , 1994 .

[39]  A. Arora,et al.  The changing technology of technological change: general and abstract knowledge and the division of , 1994 .

[40]  G. Pisano.  The R&D Boundaries of the Firm: An Empirical Analysis , 1990 .

[41]  S. Newell,et al.  Project-Based Learning and the Role of Learning Boundaries , 2004 .

[42]  David J. Teece,et al.  Joint Ventures and Collaboration in the Biotechnology Industry , 1988 .

[43]  Lowell W. Busenitz,et al.  Dynamic capabilities and venture performance: The effects of venture capitalists , 2006 .

[44]  Daniel J. Brass,et al.  POTENTIAL POWER AND POWER USE: AN INVESTIGATION OF STRUCTURE AND BEHAVIOR , 1993 .

[45]  L Lasagna,et al.  Cost of innovation in the pharmaceutical industry. , 1991, Journal of health economics.

[46]  Harry Rothman,et al.  Downstream and into deep biology: Evolving business models in ‘top tier’ genomics companies , 2006 .

[47]  A. Prencipe,et al.  Inter-project learning: processes and outcomes of knowledge codification in project-based firms , 2001 .

[48]  G. Pisano.  Can science be a business? Lessons from biotech. , 2006, Harvard business review.

[49]  F. Rothaermel.  Strategic Management Journal Research Note Incumbent's Advantage through Exploiting Complementary Assets via Interfirm Cooperation , 2022 .